Phio Pharmaceuticals shares are trading higher after the company announced that its intratumoral injection of murine PH-762 inhibited tumor growth in murine tumor models and may generate memory-specific T cells.
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals' shares surged following the announcement that its intratumoral injection, PH-762, showed promising results in inhibiting tumor growth in murine tumor models and may also generate memory-specific T cells.
April 22, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals' stock price is expected to rise in the short term due to positive results from its PH-762 intratumoral injection study, indicating potential for significant advancements in cancer treatment.
The announcement of successful preliminary results from Phio Pharmaceuticals' PH-762 study directly impacts the company's stock as it signals potential breakthroughs in cancer treatment, attracting investor interest and potentially increasing the stock's value in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100